Elizabeth Cairns / endpoints - Amgen on Saturday said its cholesterol-lowering drug Repatha cut cardiovascular events by 25% when added on top of standard therapy in high-risk patients who have never had a heart attack or stroke. Repatha is already ...
AI Summary: At AHA25 in New Orleans, researchers and clinicians showcased pivotal findings – including Amgen’s cholesterol‐lowering drug cutting first‐time cardiovascular events by 25% – while experts like Avirup Guha highlighted innovative cardio‐oncology sessions. The event spotlighted the evolving intersection between heart health and cancer care.

StackHealth RSS
StackHealth Time Machine
More StackHealth
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.